{"id":70415,"date":"2026-07-22T13:40:35","date_gmt":"2026-07-22T05:40:35","guid":{"rendered":"https:\/\/flcube.com\/?p=70415"},"modified":"2026-07-22T13:40:36","modified_gmt":"2026-07-22T05:40:36","slug":"youcare-pharmaceutical-receives-nmpa-approval-for-ykyy033-clinical-trials-across-multiple-thrombotic-indications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70415","title":{"rendered":"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Youcare Pharmaceutical<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688658:SHA\">SHA: 688658<\/a>) announced that its investigational compound <strong>YKYY033<\/strong> has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration<\/strong> (NMPA) for <strong>multiple new indications<\/strong> spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets <strong>coagulation Factor XI<\/strong> (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-indications-approved\" class=\"wp-block-heading\">Clinical Trial Indications Approved<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Specific Indications<\/th><\/tr><\/thead><tbody><tr><td><strong>Venous Thromboembolism<\/strong><\/td><td>\u2022 Treatment of deep vein thrombosis (DVT) in adults<br>\u2022 Reduction of recurrent DVT and pulmonary embolism (PE) following acute DVT<br>\u2022 Treatment and secondary prevention of cancer-associated venous thromboembolism (VTE)<\/td><\/tr><tr><td><strong>Cardiovascular<\/strong><\/td><td>\u2022 Reduction of stroke and systemic embolism risk in non-valvular atrial fibrillation (NVAF)<br>\u2022 Reduction of major cardiovascular events in chronic coronary artery disease (CAD) and\/or peripheral artery disease (PAD)<\/td><\/tr><tr><td><strong>Renal<\/strong><\/td><td>\u2022 Prevention of major thrombotic vascular events in end-stage renal disease (ESRD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound:<\/strong> YKYY033<\/li>\n\n\n\n<li><strong>Class:<\/strong> Chemically synthesized <strong>double-stranded siRNA drug<\/strong><\/li>\n\n\n\n<li><strong>Delivery System:<\/strong> Conjugated with <strong>N-acetylgalactosamine<\/strong> (GalNAc) ligand for hepatocyte-specific targeting<\/li>\n\n\n\n<li><strong>Development:<\/strong> Independently developed by <strong>Youcare Pharmaceutical<\/strong> and <strong>Hangzhou Tianlong Pharmaceutical Co., Ltd.<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Utilizes <strong>RNA interference<\/strong> (RNAi) to effectively <strong>silence messenger RNA<\/strong> (mRNA) transcribed from the <strong>coagulation Factor XI<\/strong> (FXI) gene<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Inhibits production of <strong>FXI protein<\/strong>, a key component in the intrinsic coagulation pathway<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-scientific-rationale\" class=\"wp-block-heading\">Scientific Rationale<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Targeting <strong>Factor XI<\/strong> offers a potentially <strong>safer anticoagulation strategy<\/strong> compared to traditional approaches:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced Bleeding Risk:<\/strong> FXI inhibition may provide effective antithrombotic activity while preserving hemostasis, potentially minimizing bleeding complications<\/li>\n\n\n\n<li><strong>Broad Applicability:<\/strong> Single mechanism addresses multiple thrombotic conditions across different patient populations<\/li>\n\n\n\n<li><strong>Novel Target:<\/strong> Represents next-generation anticoagulation beyond vitamin K antagonists and direct oral anticoagulants (DOACs)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-partnership\" class=\"wp-block-heading\">Development Partnership<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration between <strong>Youcare Pharmaceutical<\/strong> (SHA: 688658) and <strong>Hangzhou Tianlong Pharmaceutical<\/strong> leverages complementary expertise in RNAi therapeutics and cardiovascular drug development. This partnership accelerates clinical advancement through shared resources and specialized capabilities.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity\" class=\"wp-block-heading\">Market Opportunity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The approved indications represent substantial commercial potential:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atrial Fibrillation:<\/strong> Affects over <strong>46 million people globally<\/strong> with significant stroke risk<\/li>\n\n\n\n<li><strong>Venous Thromboembolism:<\/strong> Annual incidence of <strong>1-2 per 1,000 individuals<\/strong> in developed countries<\/li>\n\n\n\n<li><strong>Coronary Artery Disease:<\/strong> Leading cause of death worldwide with <strong>17.9 million annual fatalities<\/strong><\/li>\n\n\n\n<li><strong>Anticoagulation Market:<\/strong> Global market projected to exceed <strong>$30 billion<\/strong> by 2030<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance\" class=\"wp-block-heading\">Strategic Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This multi-indication clinical trial approval positions Youcare at the forefront of <strong>next-generation anticoagulation therapy<\/strong>. The RNAi approach could address critical unmet needs in patients who cannot tolerate current anticoagulants due to bleeding risks or contraindications.<\/p>\n\n\n\n<h2 id=\"h-company-background\" class=\"wp-block-heading\">Company Background<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Youcare Pharmaceutical<\/strong> (SHA: 688658) is a Shanghai-listed biopharmaceutical company focused on developing innovative therapeutics for cardiovascular and metabolic diseases. The company&#8217;s RNAi platform represents a strategic expansion into nucleic acid-based therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688658_20260722_H0RR.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688658_20260722_H0RR.\"><\/object><a id=\"wp-block-file--media-e91a5ee2-7220-4d41-952d-c6e0da5d6a32\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688658_20260722_H0RR.pdf\">688658_20260722_H0RR<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688658_20260722_H0RR.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e91a5ee2-7220-4d41-952d-c6e0da5d6a32\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1807,1808],"class_list":["post-70415","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-sha-688658","tag-youcare-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for multiple new indications spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets coagulation Factor XI (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70415\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications\" \/>\n<meta property=\"og:description\" content=\"Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for multiple new indications spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets coagulation Factor XI (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70415\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T05:40:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-22T05:40:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70415#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70415\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications\",\"datePublished\":\"2026-07-22T05:40:35+00:00\",\"dateModified\":\"2026-07-22T05:40:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70415\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"SHA: 688658\",\"Youcare Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70415#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70415\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70415\",\"name\":\"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-22T05:40:35+00:00\",\"dateModified\":\"2026-07-22T05:40:36+00:00\",\"description\":\"Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval from China's National Medical Products Administration (NMPA) for multiple new indications spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets coagulation Factor XI (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70415#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70415\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70415#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications - Insight, China&#039;s Pharmaceutical Industry","description":"Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval from China's National Medical Products Administration (NMPA) for multiple new indications spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets coagulation Factor XI (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70415","og_locale":"en_US","og_type":"article","og_title":"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications","og_description":"Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval from China's National Medical Products Administration (NMPA) for multiple new indications spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets coagulation Factor XI (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.","og_url":"https:\/\/flcube.com\/?p=70415","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-22T05:40:35+00:00","article_modified_time":"2026-07-22T05:40:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70415#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70415"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications","datePublished":"2026-07-22T05:40:35+00:00","dateModified":"2026-07-22T05:40:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70415"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","SHA: 688658","Youcare Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70415#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70415","url":"https:\/\/flcube.com\/?p=70415","name":"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-22T05:40:35+00:00","dateModified":"2026-07-22T05:40:36+00:00","description":"Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval from China's National Medical Products Administration (NMPA) for multiple new indications spanning thrombotic and cardiovascular disorders. The RNA interference (RNAi) therapeutic targets coagulation Factor XI (FXI) and represents a novel approach to anticoagulation with potentially improved safety profiles.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70415#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70415"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70415#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70415"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70415\/revisions"}],"predecessor-version":[{"id":70418,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70415\/revisions\/70418"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}